Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;58(2):55-71.
doi: 10.11622/smedj.2016150. Epub 2016 Sep 9.

The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma

Sanjay de Mel  1 , Yunxin Chen  2 , Sathish Kumar Gopalakrishnan  2 , Melissa Ooi  1 , Constance Teo  3 , Daryl Tan  4 , Min Li Claire Teo  2 , Allison Cy Tso  5 , Lian King Lee  5 , Chandramouli Nagarajan  2 , Yeow Tee Goh  2 , Wee Joo Chng  1
Affiliations

The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma

Sanjay de Mel et al. Singapore Med J. 2017 Feb.

Abstract

Multiple myeloma (MM) is an incurable plasma cell neoplasm with an incidence of 100 patients per year in Singapore. Major advances have been made in the diagnosis, risk stratification and treatment of MM in the recent past. The reclassification of a subset of patients with smouldering MM, based on high-risk biomarkers, and the development of the revised international staging system are among the key new developments in diagnosis and staging. The use of novel agent-based treatment has resulted in significant improvements in the survival and quality of life of many patients with MM. Determining the optimal use of proteasome inhibitors, immunomodulators and, more recently, monoclonal antibodies is an area of ongoing investigation. In this guideline, we aim to provide an overview of the management of MM, incorporating the latest developments in diagnosis and treatment.

Keywords: Singapore; evidence-based; guideline; multiple myeloma.

PubMed Disclaimer

Figures

Box 1
Box 1
Recommended investigations – screening for monoclonal gammopathy
Box 2
Box 2
Recommended investigations – confirmation of diagnosis and risk stratification
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57. - PubMed
    1. Kyle RA, Durie BG, Rajkumar SV, et al. International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7. - PMC - PubMed
    1. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–84. - PubMed
    1. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New Engl J Med. 2013;369:438–47. - PubMed
    1. Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013;122:4172–81. - PMC - PubMed

Substances